FIXX - Homology Medicines, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Homology Medicines, Inc.

One Patriots Park
Bedford, MA 01730
United States
781-301-7277
http://www.homologymedicines.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees149

Key Executives

NameTitlePayExercisedYear Born
Dr. Arthur O. TzianabosPres, CEO & Director750.39kN/A1963
Mr. Timothy P. KellyChief Technical Operations Officer481.34kN/A1969
Dr. Albert Seymour Ph.D.Chief Scientific Officer549.28kN/A1968
Dr. Saswati ChatterjeeCo-Founder & Chair of Scientific Advisory BoardN/AN/AN/A
Mr. W. Bradford SmithCFO, Treasurer & Sec.N/AN/A1956
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle, and eye in gene editing and gene therapy modalities. Its lead product candidate is HMI-102, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.

Corporate Governance

Homology Medicines, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.